Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Sees Profit-Taking Actions in CN Pharma Sector as Entry Opportunity
Recommend 56 Positive 86 Negative 55 |
||||
|
||||
|
Regarding yesterday's (23rd) hefty sell-off among Chinese biotech and pharmaceutical stocks, JPMorgan said in its report that it seemed to have been sparked by profit-taking decisions as a result of position adjustments rather than any fundamental deterioration. JPMorgan considered this pullback as a good entry opportunity to build positions in China's healthcare sector ahead of the next wave of catalyst-driven upside. The broker preferred the biotech and CXO (clinical trial service providers) sub-sectors, with INNOVENT BIO (01801.HK), SKB BIO (06990.HK), WUXI APPTEC (02359.HK), and WUXI XDC (02268.HK) as its top picks. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
